Trials / Completed
CompletedNCT01830595
Lactoferrin Treatment in HIV Patients
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Jason Baker · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Lactoferrin | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-07-01
- Completion
- 2018-01-01
- First posted
- 2013-04-12
- Last updated
- 2024-12-31
- Results posted
- 2018-09-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01830595. Inclusion in this directory is not an endorsement.